美国投行H.C. Wainwright分析师Matthew Caufield 给予诺诚健华合作伙伴zenas biopharma “买入”评级,理由是Zenas正在研发BTK抑制剂奥布替尼在治疗进展型多发性硬化症 (PMS) 方面展现出良好的前景。Caufield认为 ,凭借独特的药代动力学特征和关键性试验设计,奥布替尼依然具有差异化优势。中枢神经系统透脑性更高以及和罗氏fenebrutinib...
Source Link美国投行H.C. Wainwright分析师Matthew Caufield 给予诺诚健华合作伙伴zenas biopharma “买入”评级,理由是Zenas正在研发BTK抑制剂奥布替尼在治疗进展型多发性硬化症 (PMS) 方面展现出良好的前景。Caufield认为 ,凭借独特的药代动力学特征和关键性试验设计,奥布替尼依然具有差异化优势。中枢神经系统透脑性更高以及和罗氏fenebrutinib...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.